AbCellera Biologics (ABCL) Assets Average (2021 - 2025)
AbCellera Biologics' Assets Average history spans 5 years, with the latest figure at $1.4 billion for Q3 2025.
- For the quarter ending Q3 2025, Assets Average fell 1.68% year-over-year to $1.4 billion, compared with a TTM value of $1.4 billion through Sep 2025, down 1.68%, and an annual FY2024 reading of $1.4 billion, down 5.95% over the prior year.
- Assets Average for Q3 2025 was $1.4 billion at AbCellera Biologics, roughly flat from $1.4 billion in the prior quarter.
- The five-year high for Assets Average was $1.6 billion in Q2 2022, with the low at $1.1 billion in Q1 2021.
- Average Assets Average over 5 years is $1.4 billion, with a median of $1.4 billion recorded in 2024.
- Year-over-year, Assets Average surged 39.72% in 2022 and then dropped 8.35% in 2025.
- Tracing ABCL's Assets Average over 5 years: stood at $1.2 billion in 2021, then grew by 24.16% to $1.5 billion in 2022, then dropped by 3.01% to $1.5 billion in 2023, then decreased by 8.23% to $1.4 billion in 2024, then grew by 0.17% to $1.4 billion in 2025.
- Per Business Quant, the three most recent readings for ABCL's Assets Average are $1.4 billion (Q3 2025), $1.4 billion (Q2 2025), and $1.4 billion (Q1 2025).